Tracked deals
15
15 tracked deals across 2016-2026.
Boston, MA, United States
Founded in 1989, Riverside Partners is a Boston-based middle market private equity firm currently investing Riverside Fund VI, L.P. The firm focuses on growth-oriented companies primarily in healthcare and technology and typically invests in North American companies with $3–15M of EBITDA.
Tracked deals
15
15 tracked deals across 2016-2026.
Recent pace
3
3 tracked deals announced in the last 12 months.
Deal mix
Addon
6 addon · 5 buyout · 3 growth capital
Last 5 years
Supporting Data
Showing the 12 most recent of 15 tracked deals for Riverside Partners.
RS2 Healthcare Partners announced the completion of its investment in KMM Group and confirmed the appointment of J. Mark King as President and CEO. The release reiterates that KMM is a Hatboro, Pennsylvania-based precision contract manufacturer focused on complex medical device components and highlights RS2’s decision to rebrand and concentrate on healthcare investing.
RS2 Healthcare Partners completed an investment in KMM Group, a vertically integrated precision contract manufacturer serving the medical device industry. In connection with the investment, KMM appointed J. Mark King as President and Chief Executive Officer, while co-founders John Shegda and Eric Wilhelm took on technology and business transformation leadership roles.
RS2 Healthcare Partners (formerly Riverside Partners) completed a single-asset continuation vehicle for Loftware, a global enterprise labeling and artwork management software provider. Accel-KKR’s AKKR Strategic Capital served as lead investor, providing additional committed capital to support Loftware’s future growth and enabling RS2 to pursue new platform investments.
Boston-based private equity firm Riverside Partners has combined two of its portfolio companies, Sequoia Biotech Consulting and Syner-G BioPharma Group, into a single, integrated life‑sciences services business. The combined organization — bringing together regulatory, development, quality, and operational capabilities — has approximately 500 employees and will provide end-to-end solutions to pharmaceutical, biotechnology, and medical device clients.
Boston-based private equity firm Riverside Partners completed a growth investment in Net32, a Cary, North Carolina-based online marketplace for dental supplies. The partnership will provide capital and resources to support Net32's product innovation, vendor growth, and continued expansion of its marketplace for dental practices.
Syner-G BioPharma Group, a portfolio company of Riverside Partners, has acquired RMC Pharmaceutical Solutions, an outsourced CMC and quality management services provider based in Colorado. The add-on strengthens Syner-G's pharmaceutical science capabilities—particularly biologics and cell & gene therapy development—by integrating RMC's process and analytical development, regulatory strategy, and quality management expertise.
Convergence Networks, a Riverside Partners-backed managed IT and cybersecurity platform, has acquired Seattle-based SWAT Systems, a provider of managed IT, cybersecurity, and communication services. The add-on expands Convergence Networks' technical bench and Seattle-area footprint; financial terms were not disclosed.
Calero-MDSL, a portfolio company of Riverside Partners and Oak Hill Capital, has acquired Network Control, a boutique Telecom Expense Management (TEM) and managed mobility provider headquartered in Waverly, Iowa. The deal brings Network Control's high-touch TEM team and operations into Calero-MDSL to accelerate growth in the mid-market; Mark Hearn, Network Control's owner and CEO, will join Calero-MDSL as Vice President and General Manager of the Network Control business unit.
Riverside Partners, a Boston-based private equity firm, completed a new platform investment in UnisLink Holdings LLC, a Phoenix-headquartered provider of end-to-end revenue cycle management and population health management services. The founders will remain in management and retain a large equity stake; Riverside said it will support UnisLink's next stage of growth both organically and through acquisitions. Financial terms were not disclosed.
GrowthCurve Capital has completed an acquisition of Revecore, a provider of revenue integrity and complex claims solutions for hospitals and health systems. Riverside Partners and Revecore management will remain significant shareholders while GrowthCurve will invest to accelerate the company's technology, AI and data capabilities and support continued growth.
Syner-G BioPharma Group, a portfolio company of Riverside Partners, has acquired Impact Pharmaceutical Services, a Research Triangle Park-based provider of medical writing, regulatory strategy, and regulatory publishing services for biotech and pharmaceutical clients. The deal, which closed in late December, expands Syner-G's CMC and regulatory capabilities to better support clients across pre-IND through post-marketing stages; financial terms were not disclosed.
Riverside Partners, a Boston-based private equity firm, completed a platform investment in Sequoia Consulting Group, a San Diego–headquartered life sciences consulting firm led by founder and CEO Brandy Bullen. The partnership will support Sequoia’s growth, capability expansion, and geographic reach as the company continues to provide technical operations, quality and scientific operations, business transformation, and program/project management services to biotech, pharma, diagnostics, and medical device clients.
Turn tracked acquisition activity into an outreach-ready buyer list.